Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia

Journal of Antimicrobial Chemotherapy

Volumn 54, Issue 2, 2004, Pages 515-523

  Tellier, Guy ^a   Niederman, Michael S ^b,c   Nusrat, Roomi ^d   Patel, Manish ^d   Lavin, Bruce ^d  

^a Zoom Intl Clinical Research Group   (Canada)

^b WINTHROP UNIVERSITY HOSPITAL   (United States)

^c STONY BROOK UNIVERSITY   (United States)

^d SANOFI   (France)

Author keywords

Antimicrobial resistance; Atypical; Bacteraemia; Intracellular pathogens; Ketolides; Macrolides; Pneumococcal pneumonia

Indexed keywords

CLARITHROMYCIN; TELITHROMYCIN;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMMUNICABLE DISEASE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DYSGEUSIA; ENZYME LINKED IMMUNOSORBENT ASSAY; ERADICATION THERAPY; FEMALE; FLATULENCE; HAEMOPHILUS INFLUENZAE; HEADACHE; HUMAN; INTERMETHOD COMPARISON; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MORAXELLA CATARRHALIS; MULTICENTER STUDY; NAUSEA; OUTCOMES RESEARCH; POLYMERASE CHAIN REACTION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STREPTOCOCCUS PNEUMONIAE; THORAX RADIOGRAPHY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; COMMUNITY-ACQUIRED INFECTIONS; DOUBLE-BLIND METHOD; DRUG RESISTANCE, BACTERIAL; ELECTROCARDIOGRAPHY; ENZYME INDUCTION; FEMALE; HAEMOPHILUS INFLUENZAE; HUMANS; KETOLIDES; LIVER FUNCTION TESTS; MACROLIDES; MALE; MIDDLE AGED; MORAXELLA (BRANHAMELLA) CATARRHALIS; PNEUMONIA; SAMPLE SIZE; SPUTUM; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

EID: 4444334000     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh356     Document Type: Article

References (24)

1. Finch, R. (2001). Community-acquired pneumonia: the evolving challenge. Clinical Microbiology and Infection 7, Suppl. 3, 30-8.
2. Macfarlane, J. (1999). Lower respiratory tract infection and pneumonia in the community. Seminars in Respiratory Infections 14, 151-62.
3. File, T. M., Jr. (2000). The epidemiology of respiratory tract infections. Seminars in Respiratory Infections 15, 184-94.
4. Lim, W. S., Macfarlane, J. T., Boswell, T. C. J. et al. (2001). Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax 56, 296-301.
5. Garau, J. (1998). Changing patterns of etiology and resistance in community-acquired respiratory tract infections. Infectious Diseases in Clinical Practice 7, Suppl. 2, S92-5.
6. Felmingham, D., Reinert, R. R., Hirakata, Y. et al. (2002). Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and comparative in vitro activity of the ketolide, telithromycin. Journal of Antimicrobial Chemotherapy 50, Suppl. S1, 25-37.
7. Gruneberg, R. N. (2002). Global surveillance through PROTEKT: the first year. Journal of Chemotherapy 14, Suppl. 3, 9-16.
8. Canton, R., Morosini, M., Enright, M. C. et al. (2003). Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme. Journal of Antimicrobial Chemotherapy 52, 944-52.
9. Helms, C. M., Viner, J. P., Sturm, R. H. et al. (1979). Comparative features of pneumococcal, mycoplasmal, and Legionnaires' disease pneumonias. Annals of Internal Medicine 90, 543-7.
10. Theerthakarai, R., El Halees, W., Ismail, M. et al. (2001). Nonvalue of the initial microbiological studies in the management of nonsevere community-acquired pneumonia. Chest 119, 181-4.
11. File, T. M. (2003). Community-acquired pneumonia. Lancet 362, 1991-2001.
12. Bartlett, J. G., Dowell, S. F., Mandell, L. A. et al. (2000). Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clinical Infectious Diseases 31, 347-82.
13. Gleason, P. P. (2002). The emerging role of atypical pathogens in community-acquired pneumonia. Pharmacotherapy 22 (1 part 2), 2S-11S.
14. Baquero, F., Barrett, J. F., Courvalin, P. et al. (1998). Epidemiology and mechanisms of resistance among respiratory tract pathogens. Clinical Microbiology and Infection 4, Suppl. 2, 2S19-2S26.
15. Metlay, J. P., Hofmann, J., Cetron, M. S. et al. (2000). Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clinical Infectious Diseases 30, 520-8.
16. Pakistan Multicentre Amoxicillin Short Course Therapy (MASCOT) pneumonia study group (2002). Clinical efficacy of 3 days versus 5 days of oral amoxicillin for treatment of childhood pneumonia: a multicentre double-blind trial. Lancet 360, 835-41.
17. Ferwerda, A., Moll, H. A., Hop, W. C. J. et al. (2001). Efficacy, safety and tolerability of 3 day azithromycin versus 10 day co-amoxiclav in the treatment of children with acute lower respiratory tract infections. Journal of Antimicrobial Chemotherapy 47, 441-6.
18. Fraser, K. L. & Grossman, R. F. (1998). What new antibiotics to offer in the outpatient setting. Seminars In Respiratory Infections 13, 24-35.
19. Nicolau, D. P. (2002). Pharmacodynamic rationale for short-duration antibacterial therapy. Journal of Infection 44, Suppl. A, 17-23.
20. Balfour, J. A. & Figgift, D. P. (2001). Telithromycin. Drugs 61, 815-29.
21. Muller-Serieys, C., Soler, P., Cantalloube, C. et al. (2001). Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647). Antimicrobial Agents and Chemotherapy 45, 3104-8.
22. Namour, F., Wessels, D. H., Pascual, M. H. et al. (2001). Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses. Antimicrobial Agents and Chemotherapy 45, 170-5.
23. US Food and Drug Administration. (2003). Briefing document for the FDA/Ketek™ (telithromycin) tablets. [Online.] Briefing document for the FDA anti-infective drug products advisory committee meeting from Aventis Pharmaceuticals. Copies are available from team members. http://www.fda.gov/ohrms/dockets/ac/03/briefing/ 3919B1_01_Aventis-KETEK.pdf (20 May 2003, date last accessed).
24. Ianinni, P., Stager, W., Sharma, K. et al. (2002). Results from a 24,000 patient mega-trial comparing telithromycin (TEL) and amoxicillin-clavulanate (AM) in the treatment of community acquired respiratory tract infections [abstract 70018]. [Online.] Presented at the Forty-second Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, CA, September 27-30 2002. http://www.asmusa.org/memonly/abstracts/ AbstractView.asp?Abstract-ID=70018